hosted by  at the Whippany Marriott


Entrepreneurs Make their Two-Minute Pitch


Panel of Judges BioCapital Fund Managers

in a

Scored Competition, during lunch  12n –to- 3p


Entrepreneurs’ Booths & Posters:  Exhibit Hall Open 10-12n, and 3-4p


WINNING CEOs Will Go On to Meet One-On-One

w/ BioCapital VCs, in Reverse Venture Fair format – to 4:30p.

Our Judges are being joined by Sponsors, Angels, & thirty (30) qualified CEOs:


Rajeev Dadoo, PhD, Partner,                 SR One GlaxoSmithKline’s VC arm

Brenda Gavin, DVM, Founding Partner   Quaker BioVentures

Noah J. Kroloff, Partner,                         NGN Capital

John Clarke, Founding Partner,              Cardinal Partners

Zev Sherl, Partner                                    NewSpring Capital

Debbie Hart, President,                           BioNJ

Martin Kratchman, Founding Partner     HealthPro BioVentures



Rajeev Dadoo, PhD, Partner, SR One  serves as Director on Boards of NeuroThera-peutics Pharma and Synovex and Observer on Ipierian and Concert Pharma, and involved w/ investments in Cydex, Hypnion, Predix Pharma, Rib-X Pharma, Octoplus, Trigen, Nucleonics, & Pinnacle Pharma.  Prior, Rajeev worked in Genentech’s technology & clinical development Bio-Rad Laboratories’ product development, plus bus dev at Genome Therapeutics. Rajeev co-founded Unimicro Tech to  commercialize instrumentation for biomedical analysis.

SR One GlaxoSmithKline’s VC arm  invests globally in early stage healthcare firms pursuing innovative, break-through science+ access technology innovations from GSK creating new value using inventions for products in other industries  that can provide attractive financial returns plus significant  strategic value: in life science sectors, prefer to lead / co-lead investment. We actively syndicate and align w/ other financial investors, & do not ask for specific product rights or options. We are active investors and typically take board of directors or board observer seats. We maintain a strict firewall with GSK on confidential items received from a portfolio co or investment opportunities under review.


Brenda Gavin, DVM, Founding Partner, Quaker BioVentures  Prev. President, S.R. One, VC arm of GlaxoSmithKline. And GP, EuclidSR Partners, an independent VC fund focused on healthcare and info tech.  While at SROne  Dr. Gavin was responsible for dozens of venture + strategic investments, serving as a board member or active board observer for many portfolio companies.


Quaker Partners invests $5.0M to $25.0M in each Co.  preferring to lead or co-lead investments w/ active board involvement, seeking to deliver superior financial returns by investing in healthcare co.s that develop innovative and cost effective medical solutions across all sectors of:  pharma, biotech, healthcare services, and medical devices – tools & human diagnostics, and diversifies by investing in healthcare companies at various stages of development, from start-ups to companies that are marketing products and services.

Noah J. Kroloff, Partner, NGN Capital   Prior to VC, had many Sr operating roles:  VP Sales & Marketing of i-STAT Corp med  devices sold to Abbott Labs for $450.M, led global alliance w/ Abbott + $61.M alliance with HP Med Products.  Prior, he was an Engagement Manager at McKinsey & Co. advising leading pharma and diagnostic CEOs on R&D mgmt, portfolio strategy, & alliance formation. He’s BoD: BeneChill, Valtech Cardio, and Coagulation Sciences, Observer of Cerapedics, Inc. Member of McKinsey’s alumni advisory council and Technion NY Metro.

NGN Capital is a global healthcare VC investment fund with offices in NYC, Greenwich CT, and Heidelberg Germany, with capabilities across broad spectrum of healthcare segments including drug products, medical devices and healthcare services, with an emphasis on later-stage opportunities. In 2005 NGN closed its first healthcare fund of $250M and is now investing from its second fund: NGN BioMed Opportunity II.

NGN’s professionals were directly involved in transformational developments in healthcare that led to significant realizations for investors.   NGN’s advisors are recognized experts in their respective fields of healthcare, science and corporate value creation and work actively with NGN’s professionals.

Debbie Hart, President,  BioNJ works alongside NJ’s biotech leaders to promote business and public policy environments in NJ, WDC and beyond advancing growth and prosperity of NJ biotech companies.   She currently serves on many advisory boards for academic, government, and industry and has earned many awards.

BioNJ accomplishes its mission through excellence  ●  Ensuring acquisition and availability of appropriate human capital, BioCapital, plus resources necessary to build successful biotech products and biotech support companies in NJ;  ●  Formulating and advocating policy positions to elected officials, regulators, the media and general public; ●  Enhancing global awareness appreciation of NJ’s talents, experiences, and resources.

John Clarke, Partner, co-founded Cardinal Partners in 1997 after entering VC industry with DSV Partners in 1982. He served as interim CEO of numerous successful companies incl: Alkermes

(NASDAQ:ALKS), Arris Pharma, DNX,

Cubist Pharma (NASDAQ:CBST). He currently serves on BoD of Alnylam Pharma, (NASDAQ:ALNY), aTyr Pharma, Momenta Pharma, (NASDAQ:MNTA), Rib-X Pharma, and Verastem . He also served as BoD for Sirtris Pharma (acquired by GSK), TechRx (Acquired by NDCHealth),  Visicu (acquired by Phillips Electronics).

John is also a Trustee of Hands Together, a non-profit organization that provides health care and education support to the needy in Haiti. Prior to his VC career, he worked for GE in various sales / marketing positions.
John received his A.B. in Economics and Biology from Harvard Univ. and his MBA  Wharton School at Univ. of Pennsylvania.


Cardinal Partners invests $6.-to $12.M / company. Our criterion for new projects incl:  Large or fast growing available markets, Strong CEO, founder, team or scientist, Proprietary intellectual assets or novel tech-nology and a well-defined business model; in early stage companies across the spectrum of the healthcare economy.  Life Sciences:  since 1980s we are especially interested in novel platform technologies which will be extensible across a range of the therapeutic applications and disciplines. Many of our companies are able to fund growth very early in their development via partnerships with large pharmaceutical companies. We are frequently company co-founders, forming new entities around promising science or research. Medical Devices:  products and instruments, characterized by: strong cost-benefit propositions; large unmet market opportunities; and breakthrough innovative technology.  Healthcare IT:  goal is to fund innovative technology / service co.s which Automate broken processes of Healthcare  redefine / enhance clinical processes  automate revenue-cycle challenges, enhance communication between providers  payers and patients, and expedite the ongoing transition towards consumerism in healthcare.

Zev S. Sherl, Partner NewSpring Capital  focused exclusively in health care + life sci  industries. Prior to joining NewSpring 2003 he worked w/ Pequot Ventures managing   $1.B Prior, healthcare investor team at Behrman Capital PE managing $700M.  Prior to PE in 1997, Sr Dir, Strategic Plan-ning Value Health, largest independent pharmacy and mental health benefit mgmt  co. led to successful sale to Columbia HCA He was also US Manager Pricing Policy at Merck, prior he was InvBanker at Lehman Bros. Zev currently on BoD: Core Essence Orthopaedics, EKR Therapeutics, Immune Control, Nitric BioTherapeutic. Frmly BoD for AppTec Lab Services prior to sale to Wuxi Pharma, and Scandius BioMedical prior to its sale to Covidien.  He received a BA honors in economics Duke Univ. and MBA from Harvard Business School.

NewSpring Capital has $800 million across 3 distinct investment strategies through its family of funds:

NewSpring Growth equity capital to grow and expand  companies with a focus on business services, enabling technologies, and information technology.

NewSpring Healthcare equity capital to healthcare companies within specialty pharma, healthcare services, and medical devices.

NewSpring Mezzanine capital for expansion stage and buy out opportunities in business services, health care, info tech, and specialty manufacturing.      Principals leverage their previous experience managing and advising growth companies actually work with the senior management teams of each portfolio company to build and enhance value via:  ● Strategic guidance ● Corporate governance best practices ● Building out management teams (network of executives and recruiters) ●Client and partner introductions ●Merger and acquisition advice ● Relationships with additional equity and debt capital sources ●  Creating and evaluating exit opportunities


Martin Kratchman, Founding Manager HealthPro BioVentures provides a vast array of advisory and banking services to Healthcare & LifeSci: Capital Formation, M&A, Strategic Licensing and Partnering. He acts as Advisor & InvBank both public & private: financial offerings, pipeline enhancement / divestment, business dev. / corp restructuring. Specialty in healthcare since 1992 via Paramount BioCapital M&A Team:  Cardiome Pharm acquisition of Paralex, Inc. and Adherex’s acquisition of Oxiquant. He raised capital for Aries Fund, did risk mgmt at Chase, derivatives at First Boston, and arbitrage at CitiCorp.

HealthPro works with Clients to ● Develop strategic goals and target lists of potential investors / buyers or sellers / partners licensors and licensees,  ● Assist with presentations and due diligence dossiers ● Arrange well-vetted meetings with investors / target companies / strategic partners ● Advise on the structure, timing and pricing of the transaction terms ● Negotiate, document and close the transaction.  HealthPro has developed close relationships with institutional healthcare funds and strategic investors that look to us for innovative investment opportunities. Whether we pursue a financial or strategic investment, we will access our broad network of private equity, venture capital and high net-worth investors to meet our clients financial needs.

Already one dozen Entrepreneurs are securing slots, only 20 slots available ! 

ELEVATOR PITCH OLYMPICS   see prev. video clips.

Host:             Venture Association of New Jersey, Inc. 

Date & Time:    Mon Nov. 12th      9:00-5:00       Venue  Whippany Marriott 

Register and pay VANJ $600.   Earlybird by Oct 5th : $350.  


Register via Exhibitor Form from:  Clara Stricchiola:  or

 Dan Conley, NJAngels Life Science Investors:

CO-Producer of the Elevator Pitch Olympics is the

Entrepreneurs  University  programs

Entrepreneurs Prepare By Practicing their Fast Pitch $40. / person, 4-6p at the

Commercialization Center for Innovative Technologies                                          

#675 Route 1s, North Brunswick, NJ 08902   (GPS use #681)

Sept 13th     HOW TO Procure Angel Capital:       Tips, Tactics, Techniques


Oct. 2nd           HOW TO Procure Venture Capital:    Tips, Tactics, Techniques


Nov 6th        Funded CEOs; Advice from Next Rungs Up The VC Food Chain



Entrepreneurs University program format:

4:00p    Venture Community announcements; capital access opportunities.


4:10p    Participants Make Their One-Minute IntroductionPlus Sponsors Soapbox




5:00p    Technical Topic on:  HOW TO VENTURE interactive Q&A case-by-case – above


6:00p          Programs wrap, networking to 7:00p  Major Sponsor: 732.873.1955

NJAngels’  VenturEvaluations  help commercialize  science 

ANGELS + VCs for Lunch

By Helping Entrepreneurial CEOs  Organize Their

Unfair Commercial & Technological Advantages into

a Fundable Business Plan based on Know-How with:


NanoBio Tools, Materials, + Devices

Companion Diagnostics for Personalized Medicines, 

Vaccines, Regen+NeuroMedicine Discovery Tools,

Drug Delivery, Patient Adherence & Compliance,

Anything for Wounded Warriors, First Responders

Dx & Tx imaging niches, InfoTech to Fix Healthcare. 



# 675 Rte 1s, No. Brunswick, NJ 08902   GPS use #681.

Angels + Presenters pre-register:

VenturEvaluation workshops Teams of Three  by appointment      8-10a  $40.

ANGELS  +  VCs   LUNCH                      10-2p  $40.




10Jan’13  and then First Tuesdays through to 4June’13 Best of Best CEOs


CEO Fast Pitch Coaching: A 20-Minute Forum to Learn How CEOs Can Make

Cogent Their Company’s Venture Plan Presentation In 5-Minutes    2-4p  $40.  .


ENTREPRENEURS    UNIVERSITY            4-6p   $40 to NJEF, Inc

 Technical Programs (below) Teach CEOs:    HOW TO VENTURE 

  pre-register:  EntreUniv  or via  

Sept 13th :  How to Procure Angel Capital;           Tools, Techniques, Tactics you can use

Oct   2nd :   How to Procure Venture Capital;        Tools, Techniques, Tactics you can use

Nov   6th :    Funded CEOs;  Valuable Advice to Get to Your Next Rung UP  the VC Food Chain.



OnCallCFO  for  Fundable  Teams; 

Managing Director    NJ  Angels  Networks,   Sponsors  of

Entrepreneurs  University programs: